10-Q: Celcuity Inc. Reports Second Quarter 2024 Results, Advances Clinical Programs and Secures Funding

Celcuity Inc. reported a net loss for the second quarter of 2024, while also advancing its clinical programs and securing significant funding.

Summary

• Celcuity Inc., a clinical-stage biotechnology company, announced its financial results for the second quarter of 2024, reporting a net loss of $23.7 million, compared to a net loss of $14.6 million for the same period in 2023.
• The company's research and development expenses increased to $22.5 million for the quarter, up from $13.7 million in the prior year, primarily due to costs associated with the VIKTORIA-1 and CELC-G-201 clinical trials.
• General and administrative expenses also rose to $1.8 million, compared to $1.3 million in the same quarter of 2023.
• Celcuity secured $129 million in gross proceeds through equity and debt financings during the quarter, which is expected to fund operations through 2026.
• The company's cash and cash equivalents, along with short-term investments, totaled approximately $283.1 million as of June 30, 2024.
• Celcuity is progressing with its clinical trials, including the VIKTORIA-1 Phase 3 trial for breast cancer and the CELC-G-201 Phase 1b/2 trial for prostate cancer.
• The company also announced plans to initiate the VIKTORIA-2 Phase 3 trial for first-line treatment of HR+/HER2advanced breast cancer, with the first patient expected to be enrolled in the second quarter of 2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has secured significant funding and is progressing with its clinical trials, the increasing losses and high R&D expenses are concerning. The delay in topline data for the VIKTORIA-1 trial is also a negative factor. Overall, the sentiment is cautiously optimistic.

Positives

• Celcuity successfully raised $129 million in gross proceeds through equity and debt financings, strengthening its financial position.
• The company is actively progressing its clinical trials, including the VIKTORIA-1 and CELC-G-201 trials, and planning for the VIKTORIA-2 trial.
• The company has a strong cash position of $283.1 million, which is expected to fund operations through 2026.
• The company's lead therapeutic candidate, gedatolisib, has shown promising results in previous trials and is being evaluated in multiple clinical trials.
• The company has secured a loan agreement with Innovatus and Oxford for up to $180 million, providing additional financial flexibility.

Negatives

• Celcuity reported a significant net loss of $23.7 million for the quarter and $45.3 million for the six months ended June 30, 2024.
• Research and development expenses have increased substantially, reflecting the high costs of clinical trials.
• The company has not generated any revenue to date and is reliant on external funding.
• The company has an accumulated deficit of approximately $205.4 million as of June 30, 2024.

Risks

• The company is dependent on the clinical and commercial success of its lead drug candidate, gedatolisib.
• The company requires substantial additional financing to achieve its goals.
• There is uncertainty regarding the broad adoption of its approved products, if any, by physicians and consumers.
• The company faces significant competition in the biotechnology industry.
• Clinical trial costs are subject to change and may vary from estimates.
• The company's future success is dependent on obtaining regulatory approval for its products.
• The company's loan agreement contains financial covenants that could restrict operations.

Future Outlook

Celcuity expects to reach its enrollment target for the VIKTORIA-1 PIK3CA WT cohort in Q4 2024 and report topline data in late Q4 2024 or Q1 2025. The company also plans to initiate the VIKTORIA-2 Phase 3 trial in 2025 and believes its current cash and available borrowings will fund operations through 2026.

Management Comments

• The company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include research and development expenditures, clinical trial expenditures, expansion of business development activities and other general corporate purposes.
• Based on our current business plan, we believe that our current cash, cash equivalents and short-term investments together with available borrowings under the Innovatus Loan Agreement will provide sufficient cash to finance our operations and pay obligations when due through 2026.

Industry Context

Celcuity is operating in the competitive biotechnology industry, focusing on targeted therapies for cancer. The company's approach of using a companion diagnostic platform to identify patients likely to benefit from specific therapies aligns with the industry trend towards personalized medicine. The development of gedatolisib, a pan-PI3K/mTOR inhibitor, addresses the limitations of single-target inhibitors, which is a key area of focus in cancer drug development.

Comparison to Industry Standards

• The reported median progression-free survival (mPFS) of 48.6 months for treatment-naive patients in the gedatolisib Phase 1b trial compares favorably to published data for current first-line standard-of-care treatments for patients with HR+, HER2advanced breast cancer, such as those seen in the PALOMA-2 and PALOMA-3 studies.
• The objective overall response rates (ORR) observed in the gedatolisib Phase 1b trial, ranging from 36% to 79% in various arms, are also competitive with the ORR of 55% in the PALOMA-2 study and 25% in the PALOMA-3 study.
• The safety profile of gedatolisib, with only 7% of patients experiencing Grade 3 or 4 hyperglycemia and less than 9% discontinuing treatment in the Phase 1b trial, appears better than the toxicity profile of oral PI3K inhibitors like Piqray, which had 39% of patients experiencing Grade 3 or 4 hyperglycemia and 26% discontinuing treatment due to adverse events.
• The company's approach of using a companion diagnostic platform to identify patients likely to benefit from specific therapies is similar to other companies in the personalized medicine space, such as Foundation Medicine and Guardant Health, but Celcuity's focus on live tumor cells is a differentiator.

Stakeholder Impact

• Shareholders will be impacted by the increased net loss and the potential for dilution from equity offerings.
• Employees will be impacted by the company's continued growth and development.
• Patients will benefit from the company's efforts to develop new cancer therapies.
• Creditors will be impacted by the company's debt financing activities.
• Suppliers will be impacted by the company's increased research and development spending.

Next Steps

• The company will continue to enroll patients in the VIKTORIA-1 and CELC-G-201 clinical trials.
• The company expects to reach its enrollment target for the VIKTORIA-1 PIK3CA WT cohort in Q4 2024.
• The company plans to report topline data for the VIKTORIA-1 PIK3CA WT cohort in late Q4 2024 or Q1 2025.
• The company will initiate the VIKTORIA-2 Phase 3 trial in 2025, with the first patient expected to be enrolled in the second quarter of 2025.
• The company will continue to monitor and manage its financial resources to fund operations through 2026.

Key Dates

Keywords

gedatolisib, clinical trials, breast cancer, prostate cancer, PI3K/mTOR inhibitor, biotechnology, financing, research and development, VIKTORIA-1, CELC-G-201, VIKTORIA-2, companion diagnostic, CELsignia